Sodium phenylacetate/sodium benzoate

Drug Profile

Sodium phenylacetate/sodium benzoate

Alternative Names: AMMONUL; Sodium benzoate/sodium phenylacetate

Latest Information Update: 27 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ucyclyd Pharma
  • Developer Hyperion Therapeutics; Ucyclyd Pharma
  • Class Benzoates; Hepatoprotectants; Neuroprotectants; Phenylacetates
  • Mechanism of Action Ammonia scavengers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatic encephalopathy; Hyperammonaemia
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperammonaemia
  • Discontinued Hepatic encephalopathy

Most Recent Events

  • 21 Feb 2017 Sodium phenylacetate/sodium benzoate licensed for marketing to Swedish Orphan Biovitrum for the treatment of Hyperammonaemia
  • 07 May 2015 Hyperion Therapeutics has been acquired by Horizon Pharma
  • 12 Jun 2013 Ucyclyd exercises its option to retain sodium phenylacetate/sodium benzoate for Hyperammonaemia in patients with urea cycle disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top